Skip to main content
Fig. 3 | Arthritis Research & Therapy

Fig. 3

From: Effects of tofacitinib monotherapy on patient-reported outcomes in a randomized phase 3 study of patients with active rheumatoid arthritis and inadequate responses to DMARDs

Fig. 3

Percentage of patients with improvements ≥ the minimal clinically important difference (MCID) at month 3. Patient Global Assessment of Disease Activity (PtGA) (a), Patient Global Assessment of Pain (Pain) (b), Health Assessment Questionnaire-Disability Index (HAQ-DI) (c), Short Form-36 Physical Component Summary (SF-36 PCS) score (d), SF-36 Mental Component Summary (MCS) score (e), Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-F) (f) and SF-36 domain scores (g); *p <0.05; **p <0.01; ***p <0.0001 vs placebo. MCID ≥10 points in PtGA and Pain, ≥0.22 points in HAQ-DI, ≥2.5 points and ≥5 points in SF-36 summary and domain scores, respectively and ≥4 points in FACIT-F. BID twice daily, BP bodily pain, GH general health, MH mental health, NNT number needed to treat, PF physical function, RE role emotional, RP role physical, SE standard error, SF social functioning, VT vitality

Back to article page

Arthritis Research & Therapy

ISSN: 1478-6362

Contact us